Antimicrobial resistance (AMR) is a critical issue, with approximately 5 million global deaths associated with bacterial AMR infections in 2019, including over 1 million directly linked to bacterial AMR. This crisis is exacerbated by a shortage of cost-effective antimicrobial agents for treating multi-drug-resistant (MDR) Gram-negative bacterial infections, particularly in lower- and middle-income countries. Escherichia coli, a common cause of community urinary and bloodstream infections, has evolved to evade hospital infection control measures, leading to increased mortality, extended hospital stays, and rising healthcare costs. The emergence of cephalosporin-resistant E. coli, with associated mortalities and healthcare expenditures, underscores the urgency of addressing AMR.
The situation is further complicated by the global proliferation of CTX-M-producing E. coli during the mid-2000s and early 2010s, which has indirectly fueled the carbapenemase pandemic. Carbapenems, a critical treatment option for MDR Gram-negative infections, are now under threat due to the emergence of carbapenemase-producing E. coli. This has led to the global spread of carbapenemase and CTX-M genes among E. coli, with the ST131 clone being a significant contributor.
The detection of CTX-M-producing E. coli is challenging, and clinical laboratories have traditionally relied on time-consuming phenotypic approaches. Rapid commercial assays have been developed, but their widespread adoption is limited due to high costs and the need for additional trained personnel. The implementation of rapid, user-friendly CTX-M diagnostics could improve clinical outcomes, but robust evidence demonstrating their impact on healthcare costs and patient morbidity and mortality is lacking. Large, randomized international studies are essential to encourage uptake by clinicians and healthcare institutions, and the inclusion of these assays in clinical guidelines and surveillance programs could strengthen their relevance.
In summary, the global proliferation of CTX-M-producing E. coli and the emergence of carbapenemase-producing E. coli pose significant challenges to healthcare systems worldwide. The development and adoption of rapid, cost-effective diagnostics, along with international collaboration and research, are crucial steps towards addressing this growing threat to human health.
